Keyword: Herceptin

With biosimilar versions of its top drugs on the horizon, Roche's Genentech unit is parting ways with 223 staffers in California.

AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.

Roche in July boosted the prices of nine medicines by an average of about 3%, including blockbuster oncology drugs Herceptin, Avastin and Rituxan.

Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.

A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.

Opdivo is the first I-O drug approved in China; Dr. Reddy's faces Suboxone Film patent spat; former multinational pharma executives jump to Chinese startups.

Puma's former senior director of regulatory affairs made more than $1 million by trading on nonpublic information, authorities say.

Celltrion says its biosimilars for Herceptin and Rituxan could be approved this year after it made plant improvements to resolve and FDA warning letter.